Swiss data engine Rivia has launched a new AI-powered data review module to speed up clinical data cleaning.
The DataFindings module aims to reduce delays in drug development through continuous, automated review of clinical trial data. The add-on is used for the company’s Rivia Core platform, which is designed to unify fragmented clinical trial data into a single, structured foundation, bringing together data from different trial systems and vendors, according to the company's release.
Clinical stage drug development is often delayed due to “unresolved data issues,” causing a slower transition from clinical trial completion to data analysis and regulatory submission, according to Rivia’s CEO Erik Scalfaro.
“The increasing complexity of drug development requires a fundamentally different approach to clinical data infrastructure,” Scalfaro said.
The add-on module starts by using AI agents to help users create data review rules. Once the rules are set, the module continuously governs the trial data and looks for changes to flag for attention. Once an issue is identified, users can also review and assign tasks to team members, where there is a complete audit trail of decisions and actions stored in the platform.
U.K.-based Scancell is a design partner and first adopter of DataFindings. The cancer immunotherapy biotech hopes to use Rivia’s module to cut end-of-study data cleaning from eight weeks to just two.
“Adopting Rivia’s AI-driven clinical data analysis tool DataFindings has enabled Scancell to translate its phase 2 clinical trial data with greater granularity, confidence and efficiency,” Joe Thornton, vice president, clinical operations at Scancell, said in the release.
Earlier this year, Rivia bagged $15 million in series A funds to scale its platform and embed intelligence capabilities to accelerate clinical development.